Genome remodelling in a basal-like breast cancer metastasis and xenograft
…, RS Fulton, LL Fulton, RM Abbott, J Hoog… - Nature, 2010 - nature.com
Massively parallel DNA sequencing technologies provide an unprecedented ability to
screen entire genomes for genetic changes associated with tumour progression. Here we …
screen entire genomes for genetic changes associated with tumour progression. Here we …
[HTML][HTML] Whole-genome analysis informs breast cancer response to aromatase inhibition
…, J Luo, VJ Suman, JW Wallis, BA Van Tine, J Hoog… - Nature, 2012 - nature.com
To correlate the variable clinical features of oestrogen-receptor-positive breast cancer with
somatic alterations, we studied pretreatment tumour biopsies accrued from patients in two …
somatic alterations, we studied pretreatment tumour biopsies accrued from patients in two …
CDK4/6 inhibition triggers anti-tumour immunity
…, JM Ubellacker, S Xie, O Metzger-Filho, J Hoog… - Nature, 2017 - nature.com
Cyclin-dependent kinases 4 and 6 (CDK4/6) are fundamental drivers of the cell cycle and are
required for the initiation and progression of various malignancies 1 , 2 . Pharmacological …
required for the initiation and progression of various malignancies 1 , 2 . Pharmacological …
[PDF][PDF] Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts
…, J Shao, R Crowder, W Liu, A Prat, X He, S Liu, J Hoog… - Cell reports, 2013 - cell.com
To characterize patient-derived xenografts (PDXs) for functional studies, we made whole-genome
comparisons with originating breast cancers representative of the major intrinsic …
comparisons with originating breast cancers representative of the major intrinsic …
[HTML][HTML] Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor–rich …
Purpose Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving surgery
(BCS) for estrogen receptor (ER)–positive breast cancer. To study this treatment option, …
(BCS) for estrogen receptor (ER)–positive breast cancer. To study this treatment option, …
[HTML][HTML] Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the …
Purpose To determine the pathologic complete response (pCR) rate in estrogen receptor (ER)–positive
primary breast cancer triaged to chemotherapy when the protein encoded by the …
primary breast cancer triaged to chemotherapy when the protein encoded by the …
NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor–positive breast cancer
…, J Luo, DW Northfelt, M Goetz, A Forero, J Hoog… - Clinical Cancer …, 2017 - AACR
Purpose: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor–positive
(ER + ) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) …
(ER + ) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) …
Vav1/2/3-null mice define an essential role for Vav family proteins in lymphocyte development and activation but a differential requirement in MAPK signaling in T and …
…, AV Miletic, FW Alt, R Faccio, T Brown, J Hoog… - The Journal of …, 2003 - rupress.org
The Vav family of Rho guanine nucleotide exchange factors is thought to orchestrate
signaling events downstream of lymphocyte antigen receptors. Elucidation of Vav function has …
signaling events downstream of lymphocyte antigen receptors. Elucidation of Vav function has …
[HTML][HTML] Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models
…, Z Guo, WT Schaiff, L Lin, J Hoog… - The Journal of …, 2012 - Am Soc Clin Investig
Oncogenic Ras and p53 loss-of-function mutations are common in many advanced sporadic
malignancies and together predict a limited responsiveness to conventional chemotherapy. …
malignancies and together predict a limited responsiveness to conventional chemotherapy. …
PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor–Positive Breast Cancer
RJ Crowder, C Phommaly, Y Tao, J Hoog, J Luo… - Cancer research, 2009 - AACR
Several phosphoinositide 3-kinase (PI3K) catalytic subunit inhibitors are currently in clinical
trial. We therefore sought to examine relationships between pharmacologic inhibition and …
trial. We therefore sought to examine relationships between pharmacologic inhibition and …